Hospital service interventions and improving survival of AIDS patients St Mary's Hospital, London, 1982-1991

International Journal of STD and AIDS

Volumn 9, Issue 5, 1998, Pages 280-290

  Beck, Eduard J ^a,b   Mandalia, Sundhiya ^a   Miller, David L ^a   Harris, John R W ^a  

^a ST MARY S HOSPITAL   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

AIDS; Health services; PCP; Survival

Indexed keywords

ACICLOVIR; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTIMYCOBACTERIAL AGENT; ANTIRETROVIRUS AGENT; COTRIMOXAZOLE; DAPSONE; FOSCARNET; METHYLPREDNISOLONE; PENTAMIDINE ISETHIONATE; STEROID; SULFAMETHOXAZOLE; TRIMETHOPRIM; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; DEMOGRAPHY; FATALITY; HEMOGLOBIN DETERMINATION; HOSPITAL SERVICE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; NEBULIZATION; ORAL DRUG ADMINISTRATION; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; SURVIVAL; SURVIVAL TIME; TREATMENT OUTCOME;

EID: 0031810171     PISSN: 09564624     EISSN: None     Source Type: Journal    
DOI: 10.1258/0956462981922214     Document Type: Article

References (64)

1. Chien SM, Rawji M, Mintz S, Rachlis A, Chan CK. Changes in hospital admission pattern in patients with human immunodeficiency virus infection in the era of Pneumocystis carinii prophylaxis. Chest 1992;102:1035-9
2. Wall P, Porter K, Noone A, Goldberg DJ. Changing incidence of Pneumocystis carinii pneumonia as initial AIDS defining disease in the United Kingdom. AIDS 1993;7:1523-5
3. Delmas M-C, Schwoebel V, Heisterkamp SH, et al. Recent trends in Pneumocystis carinii pneumonia as AIDS-defining disease in nine European countries. J AIDS and Hum Retr 1994;9:74-80
4. Peters BS, Beck EJ, Coleman DG, et al. Changing disease patterns in patients with AIDS in a referral centre in the United Kingdom: the changing face of AIDS. BMJ 1991;302:203-7
5. Whitmore-Overton SE, Tillett HE, Evans BG, Allardice GM. Improved survival from diagnosis of AIDS in adult cases in the United Kingdom and bias due to reporting delays. AIDS 1993;7:415-20
6. Rothenberg R, Woelfel M, Stoneburner R, Milberg J, Parker R, Truman B. Survival with the acquired immunodeficiency syndrome. N Engl J Med 1987;317:1297-302
7. Blum S, Singh TP, Gibbons J, et al. Trends in survival among persons with acquired immunodeficiency syndrome in New York City. Am J Epidemiol 1994;139:351-61
8. Pedersen C, Gerstoft J, Tauris P, et al. Trends in survival of Danish AIDS patients from 1981 to 1989. AIDS 1990;4:1111-16
9. Solomon PJ. The survival distribution of Australian AIDS patients. In: Solomon PJ, Fazekas de St Goth C, Wilson SR, eds. Projections of Acquired Immune Deficiency Syndrome in Australia. NCEPH Working Papers. ANU, Canberra, April 1990:61-70
10. Luo K, Law M, Kaldore J, McDonald AM, Cooper DA. The role of initial AIDS-defining illness in survival following AIDS. AIDS 1995;9:57-63
11. Bindels RJ, Poos RMJ, Jong JT, Mulder JW, Jager HJC, Coutinho RA. Trends in mortality among AIDS patients in Amsterdam, 1982-1989. AIDS 1991;5:853-8
12. Harris JE. Improved short-term survival of AIDS patients initially diagnosed with Pneumocystis carinii pneumonia, 1984 though 1987. JAMA 1990;263:397-401
13. Lemp GF, Payne SF, Neal D, Temelso T, Rutherford GW. Survival trends for patients with AIDS. JAMA 1990;263:402-6
14. Chang H-G, Morse DL, Noonan C, et al. Survival and mortality patterns of an acquired immunodeficiency syndrome (AIDS) cohort in New York State. Am J Epidemiol 1993;138:341-9
15. Moore RD, Hidalgo J, Sugland BW, Chaisson RE. Zidovudine and the natural history of the acquired immunodeficiency syndrome. N Engl J Med 1991;324:1412-16
16. Lafferty WE, Glidden D, Hopkins SG. Survival trends of people with AIDS in Washington State. Am J Pub Health 1991;81:217-19
17. Jacobson LP, Kirby AJ, Polk S, et al. Changes in survival after acquired immunodeficiency syndrome (AIDS): 1984-1991. Am J Epidemiol 1993;138:952-64
18. Lemp GF, Hirozawa AM, Cohen JB, et al. Survival for women and men with AIDS. J Infect Dis 1992;166:74-9
19. Solomon PJ, Wilson SR, Swanson CE, Cooper DA. Effect of zidovudine on survival of patients with AIDS in Australia. Med J Aust 1990;153:254-7
20. Pitkin AD, Grant AD, Foley NM, Miller RF. Changing patterns of respiratory disease in HIV positive patients in a referral centre in the United Kingdom between 1986-7 and 1990-1. Thorax 1993;48:204-7
21. Graham NMH, Zeger SL, Park LP, et al. Effect of zidovudine and Pneumocystis carinii pneumonia prophylaxis on progression of HIV-1 infection to AIDS. Lancet 1991;338:265-9
22. Graham NMH, Zeger SL, Park LP, et al. The effect on survival of early treatment of human immunodeficiency virus infection. N Engl J Med 1992;326:1037-42
23. Fischl MA, Richman DD, Grieco MH, et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. N Engl J Med 1987;317:185-91
24. Dournon E, Matheron S, Rozenbaum W, et al. Effects of zidovudine in 365 consecutive patients with AIDS or AIDS-related complex. Lancet 1988;II:1297-302
25. Fischl M, Dickinson G, La Vioe L. Safety and efficacy of sulfamethoxazole and trimethoprim chemoprophylaxis for Pneumocystis carinii pneumonia in AIDS. JAMA 1988;259:1185-9
26. Rutherford GW. Long-term survival in HIV-1 infection. BMJ 1994;304:283-4
27. Osmond D, Charlebois E, Land W, Shiboski S, Moss A. Changes in AIDS survival time in two San Francisco cohorts of homosexual men, 1983 to 1993. JAMA 1994;14:1083-7
28. Bennett CL, Garfinkle JB, Greenfield S, et al. The relation between hospital experience and in-hospital mortality for patients with AIDS-related PCP. JAMA 1989;261:2975-9
29. Cotton DJ. Improving survival in acquired immunodeficiency syndrome: is experience everything? JAMA 1989;261:3016-17
30. Stone ES, Seage GR, Hertz T, Epstein AM. The relation between hospital experience and mortality for patients with AIDS. JAMA 1992;268:2655-61
31. Kitahata MM, Koepsell TD, Deyo RA, Maxwell CL, Dodge WT, Wagner EH. Physicians' experience with the acquired immunodeficiency syndrome as a factor in patients' survival. N Engl J Med 1996;334:701-6
32. Beck EJ, French PD, Helbert MH, et al. Improved outcome of Pneumocystis carinii pneumonia in AIDS patients: a multifactorial treatment effect. Int J STD AIDS 1992;3:182-7
33. Beck EJ, French PD, Helbert MH, et al. Empirically treated Pneumocystis carinii pneumonia in London 1983-1989. Int J STD AIDS 1992;3:285-7
34. Beck EJ, Kennelly J, McKevitt C, et al. Changing use of hospital services and costs at a London AIDS referral centre 1983-1989. AIDS 1994;8:367-77
35. Beck EJ, Whitaker L, Kennelly J, et al. Changing presentation and survival, service utilization and costs for AIDS patients: insights from a London referral centre. AIDS 1994;8:379-84
36. CDC. Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. MMWR 1987;36(1S):3S-15S
37. CDSC. AIDS Surveillance and HIV Death Clinical Report Form. London: PHLS Communicable Disease Surveillance Centre, April 1989.
38. Miller RF, Godfrey-Faussett P, Semple SJG. Nebulised pentamidine as treatment for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. Thorax 1989;44:565-9
39. MacFadden DK, Hyland RH, Inouye R, Edelson JD, Rodriguez CH, Rebuck AS. Corticosteroids as adjunctive therapy in treatment of Pneumocystis carinii pneumonia in patients with acquired immunodeficiency syndrome. Lancet 1987;I:1477-9
40. R User's Guide, Version 6, 4th Edition, Volume 2, Cary NC, USA, 1989
41. Armitage P, Berry G. Statistical Methods in Medical Research, 2nd edn. Oxford: Blackwell Scientific Publications, 1987:387-93, 396-9
42. Mitchell D. Respiratory Medicine Revision. London: Churchill-Livingstone, 1986:210
43. Beck EJ, Kupek EJ, Compels MM, Pinching AJ. Correlation between total and CD4 lymphocyte counts in HIV infection: not making the good an enemy of the not so perfect. Int J STD AIDS 1996;7:422-8
44. NHS Executive. Hospital and Community Health Services Revenue (pay and prices) Inflation Index. Finance and Performance Department A, Quarry House, Leeds, August 1995
45. Beck EJ, McKevitt C, Kennelly J, Whitaker L, Wadsworth J, Miller DL. Hospital Service Provision for People with AIDS and HIV Infection: a Report for the Department of Health 3992. Academic Department of Public Health, St Mary's Hospital Medical School, London UK, 1991
46. Poznansky MC, Coker R, Skinner C, et al. HIV positive patients first presenting with an AIDS defining illness: characteristics and survival. BMJ 1995;311:156-8
47. Porter K, Wall PG, Evans BG. Factors associated with lack of awareness of HIV infection before diagnosis of AIDS. BMJ 1993;307:20-3
48. Lundgren JD, Barton SE, Katlama C, et al. Changes in survival over time after a first episode of Pneumocystis carinii pneumonia for European patients with acquired immunodeficiency syndrome. Arch Intern Med 1995;155:822-8
49. Lundgren JD, Philips AN, Pedersen C, et al. Comparison of longterm prognosis of patients with AIDS treated and not treated with zidovudine. JAMA 1994;271:1088-92
50. Brettle RP, McNeil AJ, Gore SM, Bird AG, Leen CSL, Richardson A. The Edinburgh City Hospital cohort: analysis of enrolment, progression and mortality by baseline covariates. QJM 1995;88:479-91
51. Ioannidis JPA, Cappelleri JC, Lau J, et al. Early or deferred zidovudine treatment therapy in HIV-infected patients without an AIDS-defining illness. Ann Intern Med 1995;122:856-66
52. Richmond DD. Resistance of clinical isolates of human immunodeficiency virus to antiretroviral agents. Antimicrob Agents Chemother 1993;37:1207-13
53. Yarchoan R, Pluda JM, Thomas RV, et al. Longterm toxicity/activity profile or 2′,3′-dideoxyinosine in AIDS of AIDS-related complex. Lancet 1990;336:526-9
54. Stein DS, Graham NMH, Park LPP, et al. The effect of the interaction of acyclovir with zidovudine on progression to AIDS and survival. Ann Intern Med 1994;121:100-8
55. Beck EJ, Kupek EJ, Petrou S, et al. Survival and the use and costs of hospital services for London AIDS patients treated with AZT. Int J STD AIDS 1996;7:507-12
56. Erbelding EJ, Moore RD, Chaisson RE. Acyclovir in combination with zidovudine does not prolong survival in advanced HIV disease (Abstract Mo.B.1141). XI International Conference on AIDS. Vancouver, Canada, 7-12 July 1996
57. Youle MS, Gazzard BG, Johnson MA, et al. Effects of high-dose oral acyclovir on herpes virus disease and survival in patients with advanced HIV disease: a double-blind, placebo controlled study. AIDS 1994;8:641-9
58. Glesby MJ, Hoover DR. Survivor treatment selection bias in observational studies: examples from the AIDS literature. Ann Intern Med 1996;124:999-1005
59. McCann K. The work of a specialist AIDS home support team: the views and experiences of patients using the service. J Adv Nurs 1991;16:832-6
60. Wadsworth E, McCann K. Attitudes towards and use of general practitioner services among homosexual men with HIV infection or AIDS. Br J Gen Pract 1992;42:107-10
61. Beck EJ. Counting the cost of HIV service provision in England: where do we go from here? J HIV Comb Therapy 1997;2:29-32
62. Delta Coordinating Committee. Delta: a randomized double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV infected individuals. Lancet 1996;348:283-91
63. Bartlett JG. Protease inhibitors of HIV infection. Ann Intern Med 1996;124:1086-8
64. Hammer SM. Advances in antiretroviral therapy and viral load monitoring. AIDS 1996;335:1099-106